133 related articles for article (PubMed ID: 25356663)
1. Testing assay linearity over a pre-specified range.
Yang H; Novick SJ; LeBlond D
J Biopharm Stat; 2015; 25(2):339-50. PubMed ID: 25356663
[TBL] [Abstract][Full Text] [Related]
2. Using tolerance intervals for assessment of pharmaceutical quality.
Dong X; Tsong Y; Shen M; Zhong J
J Biopharm Stat; 2015; 25(2):317-27. PubMed ID: 25356617
[TBL] [Abstract][Full Text] [Related]
3. Analytical procedure validation and the quality by design paradigm.
Rozet E; Lebrun P; Michiels JF; Sondag P; Scherder T; Boulanger B
J Biopharm Stat; 2015; 25(2):260-8. PubMed ID: 25357001
[TBL] [Abstract][Full Text] [Related]
4. Statistical considerations in setting product specifications.
Dong X; Tsong Y; Shen M
J Biopharm Stat; 2015; 25(2):280-94. PubMed ID: 25358110
[TBL] [Abstract][Full Text] [Related]
5. Guest editors' note: special issue on recent developments in statistical approaches for chemistry and manufacturing control (CMC) and quality-by-design(QbD).
Tsong Y; Yang H
J Biopharm Stat; 2015; 25(2):233. PubMed ID: 25437635
[No Abstract] [Full Text] [Related]
6. Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay.
Shen M; Dong X; Tsong Y
J Biopharm Stat; 2015; 25(2):269-79. PubMed ID: 25356783
[TBL] [Abstract][Full Text] [Related]
7. Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products.
Tsong Y; Dong X; Shen M; Lostritto RT
J Biopharm Stat; 2015; 25(2):328-38. PubMed ID: 25357132
[TBL] [Abstract][Full Text] [Related]
8. Dissolution curve comparisons through the F(2) parameter, a Bayesian extension of the f(2) statistic.
Novick S; Shen Y; Yang H; Peterson J; LeBlond D; Altan S
J Biopharm Stat; 2015; 25(2):351-71. PubMed ID: 25357203
[TBL] [Abstract][Full Text] [Related]
9. One- and two-stage Arrhenius models for pharmaceutical shelf life prediction.
Fan Z; Zhang L
J Biopharm Stat; 2015; 25(2):307-16. PubMed ID: 25358076
[TBL] [Abstract][Full Text] [Related]
10. A quality by design approach for longitudinal quality attributes.
Lebrun P; Giacoletti K; Scherder T; Rozet E; Boulanger B
J Biopharm Stat; 2015; 25(2):247-59. PubMed ID: 25360720
[TBL] [Abstract][Full Text] [Related]
11. Non-normal random effects models for immunogenicity assay cut point determination.
Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
[TBL] [Abstract][Full Text] [Related]
12. A statistical approach to determining criticality of residual host cell DNA.
Yang H; Wei Z; Schenerman M
J Biopharm Stat; 2015; 25(2):234-46. PubMed ID: 25358029
[TBL] [Abstract][Full Text] [Related]
13. A Generalized Pivotal Quantity Approach to Analytical Method Validation Based on Total Error.
Yang H; Zhang J
PDA J Pharm Sci Technol; 2015; 69(6):725-35. PubMed ID: 26659103
[TBL] [Abstract][Full Text] [Related]
14. Estimation of the probability of passing the USP dissolution test.
Wang H
J Biopharm Stat; 2007; 17(3):407-13. PubMed ID: 17479390
[TBL] [Abstract][Full Text] [Related]
15. On statistical evaluation of the linearity in assay validation.
Hsieh E; Liu JP
J Biopharm Stat; 2008; 18(4):677-90. PubMed ID: 18607801
[TBL] [Abstract][Full Text] [Related]
16. Flexibility and applicability of β-expectation tolerance interval approach to assess the fitness of purpose of pharmaceutical analytical methods.
Bouabidi A; Talbi M; Bourichi H; Bouklouze A; El Karbane M; Boulanger B; Brik Y; Hubert P; Rozet E
Drug Test Anal; 2012 Dec; 4(12):1014-27. PubMed ID: 22615163
[TBL] [Abstract][Full Text] [Related]
17. Assessing parallelism prior to determining relative potency.
Hauck WW; Capen RC; Callahan JD; De Muth JE; Hsu H; Lansky D; Sajjadi NC; Seaver SS; Singer RR; Weisman D
PDA J Pharm Sci Technol; 2005; 59(2):127-37. PubMed ID: 15971545
[TBL] [Abstract][Full Text] [Related]
18. Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols. Part 3. Final report on a statistical procedure for determining equivalence.
Christopher D; Adams W; Amann A; Bertha C; Byron PR; Doub W; Dunbar C; Hauck W; Lyapustina S; Mitchell J; Morgan B; Nichols S; Pan Z; Singh GJ; Tougas T; Tsong Y; Wolff R; Wyka B
AAPS PharmSciTech; 2007 Nov; 8(4):E90. PubMed ID: 18181550
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the recovery spread in analytical development and routine quality control--based on the ICH quality guideline Q2B.
Schepers U; El Deeb S; Ermer J; Wätzig H
J Pharm Biomed Anal; 2007 Jan; 43(2):708-10. PubMed ID: 16904281
[TBL] [Abstract][Full Text] [Related]
20. Simple Approach to Calculate Random Effects Model Tolerance Intervals to Set Release and Shelf-Life Specification Limits of Pharmaceutical Products.
Montes RO; Burdick RK; Leblond DJ
PDA J Pharm Sci Technol; 2019; 73(1):39-59. PubMed ID: 30361286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
